Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Zota Health Care Ltd Performance

Today's Low
472.00
arrowIcon
Today's High
477.45
52 Wk Low
271.95
arrowIcon
52 Wk High
555.00


Open

476

Traded Value (Cr)

43.44 L

Prev. Close

472.35

VWAP

474.54

Volume

12,890

Face Value

10

Zota Health Care Ltd Fundamentals

Market Cap
₹ 1,224 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
11.99
Debt to Equity
0.49
ROE
-10.14 %
EPS (TTM)
0.00
Dividend Yield
0.21%
Book Value
39.50

Click here to know more about Fundamentals

Zota Health Care Ltd Financials

Zota Health Care Ltd Financials

Zota Health Care Ltd Shareholding Pattern

Held By Apr 2024 Mar 2024 Dec 2023 Sep 2023
Promoters 64.45 % 66.15 % 66.15 % 66.16 %
Retail 23.53 % 21.96 % 22.43 % 22.50 %
Others 12.02 % 11.89 % 11.43 % 11.33 %
FII 0.00 % 0.00 % 0.00 % 0.02 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

64.45%

Retail

23.53%

Others

12.02%

FII

0.00%

Mutual Funds

0.00%

Promoters

66.15%

Retail

21.96%

Others

11.89%

FII

0.00%

Mutual Funds

0.00%

Promoters

66.15%

Retail

22.43%

Others

11.43%

FII

0.00%

Mutual Funds

0.00%

Promoters

66.16%

Retail

22.50%

Others

11.33%

FII

0.02%

Mutual Funds

0.00%

Resistance and Support

₹475.95

PIVOT

resistance-arrow
Resistance
First Resistance₹481.200
Second Resistance₹490.050
Third Resistance₹495.300
support-arrow
Support
First Resistance₹467.100
Second Resistance₹461.850
Third Resistance₹453.000
RSI44.936
MACD-7.966
ADX11.464
CCI-145.897

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day12,8905,43759.38
Week13,4507,81557.21
1 Month17,0729,52260.99
6 Months12,8906,62451.39

About Zota Health Care Ltd

Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products. The Company was incorporated in July 12, 2000 and is based out of Surat, Gujarat. The Company meets the requirements of millions of people by increasing access to high-quality, affordable medicines for chronic illnesses including heart disease, diabetes, thyroid disease, and others, giving India's pharmaceutical industry a boost. The Company has three business verticals: Marketing-a traditional business vertical, and driving business verticals - Exports and Retail harmacy Chain. Through its chain, Davaindia, the largest private-sector generic pharmacy chain, the Company is making strong inroads into the generic retail pharmacy business. The Company's state-of-the-art manufacturing facility at Sachin SEZ serves customers in more than 30 countries. Davaindia is a retail generic pharmacy chain whose core value proposition is providing quality generic medicines at substantial discounts, i.e. 30% to 90%, to their branded equivalents. Davaindia focuses on private-label products in the medicinal, OTC, and ayurvedic categories, with a greater emphasis on chronic therapies and ailments. The Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products through the Company's distribution network across India. In domestic Marketing business, the Company procures finished dosage forms (FDFs) from domestic formulation manufactures and then market them under its portfolio of brands. It has a set of manufacturing partners recognized by the WHO with a rigorous focus on product quality. With a portfolio of more than 3000 products in various categories, such as generics, OTC products, allopathic, ayurvedic, etcetera, the Company cater to a variety of ailments. Currently, the Company has over 1050 distributors spread around the country. Instead of the Company directly engaging in sales, distribution, and promotion activities, its distributors engage in ethical marketing or other sales, distribution, and promotion activities on their own. Instead, it provide distributors directly with incentives to help them sell products more effectively. Secondly, the exports business vertical started in 2010, following the establishment of formulations manufacturing facility in the Sachin SEZ. The Company is required to export products from this unit in accordance with the laws governing this SEZ. At present, it has product approvals in 30 countries, particularly in the semi-regulated and regulated markets in the African, Asian, CIS, and Latin American countries. In this facility, the Company make around 250 formulations for direct exports and contract manufacturing. . At present, the Company has 253 dossiers approved across multiple countries, and another 311 dossiers have been filed and are pending approval. It significantly increased efforts and investments towards product registration, the results of which are now apparent in the form of product approvals and expansion of export operations. In the Retail Pharmacy Chain business vertical, the Company operates a chain of pharmacy stores under the brand - 'Davaindia'. Davaindia focuses only on private-label products in the medicinal, OTC, and ayurvedic categories, with a greater emphasis on chronic therapies and ailments. This concept started with three pilot stores in 2017 and has been scaled up to become the largest private-sector generic pharmacy chain with more than 591 stores as of March 2021. Davaindia operates on a unique asset-light franchise model for majority stores. These stores are engaged in exclusive sales of Davaindia products, with more than 95% of products being private-label. In all areas and media, such as TV commercials, printing, digital & social media, radio, among others, the Company has undertaken bold and aggressive marketing and promotion activities with the firm intention of creating top-of-the-mind brand recall for Davaindia. Davaindia - being a front-runner in private sector generic pharmacy has also assumed the responsibility to create awareness, propagate virtues and debunk misconceptions about generic drugs. Marketing efforts are receiving very encouraging results from prospective franchisees and potential customers. The Company witnessed a substantial improvement in average wallet spend, footfall at stores, and the number of inquiries for new franchisees with aggressive marketing campaigns. The Company has started a series of promotions, including TV and digital advertisements featuring Mr Kapil Dev. Mr Kapil Dev, as an icon, stands for integrity, excellence and willpower, the Company strongly feels he is the perfect fit for endorsing the culture and spirit of Davaindia and Zota Health Care Limited.

Managing Director

Moxesh Zota

Founded

2000

NSE Symbol

ZOTA

Zota Health Care Ltd Management

NameDesignation
Ketankumar ZotaChairman & Non Executive Dir.
Moxesh ZotaManaging Director
Kamlesh ZotaWhole-time Director
Himanshu ZotaWhole-time Director
Manukant ZotaWhole-time Director
Varsaben MehtaIndependent Director
Ashvin VariyaCompany Secretary
Bhumi Maulik DoshiAddtnl Independent Director
Dhiren Prafulbhai ShahIndependent Director
Jayshreeben N MehtaIndependent Director

Zota Health Care Ltd News

Zota Health Care reports consolidated net loss of Rs 2.94 crore in the December 2023 quarter
Sales rise 34.20% to Rs 46.93 crore
Zota Health Care to convene board meeting
On 8 February 2024
Zota Health Care reports consolidated net loss of Rs 1.65 crore in the September 2023 quarter
Sales rise 16.23% to Rs 45.27 crore
Zota Health Care to discuss results
On 10 November 2023
Zota Health Care schedules AGM
On 29 September 2023
Zota Health Care reports consolidated net loss of Rs 2.84 crore in the June 2023 quarter
Sales rise 32.41% to Rs 38.65 crore
Zota Health Care to declare Quarterly Result
On 14 August 2023
Zota Health Care schedules EGM
On 12 July 2023
Zota Health Care to hold board meeting
On 15 June 2023
Board of Zota Health Care recommends final dividend
Of Rs 1 per share

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
ADANIENT₹ 3,18,886 Cr
₹ 2,797.25
(1.11 %)
112.24
AEGISCHEM₹ 21,010 Cr
₹ 598.60
(3.40 %)
47.63
CELLO₹ 18,510 Cr
₹ 872.20
(-0.83 %)
487.63
REDINGTON₹ 16,233 Cr
₹ 207.65
(2.64 %)
15.53
HONASA₹ 13,910 Cr
₹ 429.00
(0.15 %)
145.82

Zota Health Care Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Zota Health Care Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Zota Health Care Ltd's share price is ₹474.40 as of May 10, 2024

Zota Health Care Ltd's P/E ratio is 0.00 times as of May 10, 2024.

Zota Health Care Ltd's most recent financial reports indicate a price-to-book ratio of 11.99, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Zota Health Care Ltd's market is 1,225 Cr as on May 10, 2024.

The current financial records of Zota Health Care Ltd show a -10.14% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Zota Health Care Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Zota Health Care Ltd's 52-week high and low as of May 10, 2024 are ₹477.45 and ₹472 respectively.

As of the Apr 2024 quarter, the promoter shareholding in Zota Health Care Ltd stands at 64.45%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 0.00% to 0.00%.